| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5695284 | Gynecologic Oncology | 2017 | 14 Pages |
Abstract
Regardless the high heterogeneity of the analyzed studies, the present review suggests that adjunct metformin treatment may assist in the reversal of atypical endometrial hyperplasia to normal endometrial histology, in the reduction of cell proliferation biomarkers implicated in tumor progression, and in the improvement of overall survival in endometrial cancer. Further work on prospective controlled trials designed to address the effects of adjunct metformin on clinical outcomes is necessary for definite conclusions.
Related Topics
Health Sciences
Medicine and Dentistry
Obstetrics, Gynecology and Women's Health
Authors
Cinthia G. Meireles, Sidney A. Pereira, Luciana P. Valadares, Daniela F. Rêgo, Luiz A. Simeoni, Eliete N.S. Guerra, Adriana Lofrano-Porto,